Chardan Capital Has Positive Outlook of RCKT FY2025 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Research analysts at Chardan Capital lifted their FY2025 earnings estimates for Rocket Pharmaceuticals in a note issued to investors on Sunday, March 2nd. Chardan Capital analyst Y. Livshits now expects that the biotechnology company will post earnings per share of ($1.25) for the year, up from their previous estimate of ($2.75). Chardan Capital has a “Buy” rating and a $54.00 price target on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.06.

Other research analysts also recently issued reports about the company. Needham & Company LLC lowered their target price on Rocket Pharmaceuticals from $52.00 to $42.00 and set a “buy” rating for the company in a research report on Friday, February 28th. The Goldman Sachs Group lowered their price objective on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a “neutral” rating for the company in a research report on Monday. Leerink Partners reduced their target price on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating on the stock in a report on Tuesday, November 19th. Canaccord Genuity Group decreased their target price on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Scotiabank lifted their price target on Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Monday. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $42.30.

Rocket Pharmaceuticals Stock Performance

NASDAQ RCKT opened at $8.99 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. Rocket Pharmaceuticals has a 1-year low of $8.25 and a 1-year high of $28.73. The business has a 50 day simple moving average of $10.73 and a two-hundred day simple moving average of $14.48. The stock has a market capitalization of $819.50 million, a PE ratio of -3.27 and a beta of 0.98.

Institutional Trading of Rocket Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Rocket Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 582 shares during the last quarter. Rhumbline Advisers boosted its holdings in Rocket Pharmaceuticals by 1.3% during the 4th quarter. Rhumbline Advisers now owns 99,339 shares of the biotechnology company’s stock valued at $1,249,000 after acquiring an additional 1,242 shares during the period. Envestnet Asset Management Inc. grew its position in Rocket Pharmaceuticals by 4.1% in the 4th quarter. Envestnet Asset Management Inc. now owns 32,422 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 1,280 shares during the last quarter. Arizona State Retirement System increased its stake in Rocket Pharmaceuticals by 8.4% in the fourth quarter. Arizona State Retirement System now owns 19,826 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 1,528 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Rocket Pharmaceuticals by 1.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,633 shares of the biotechnology company’s stock worth $2,210,000 after purchasing an additional 1,561 shares during the last quarter. Institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.